University of Cologne | MedPath Search

Clinical Trials

Find the latest clinical trials by condition, location & phase

Browse and search for drug information and related clinical trials

Explore a comprehensive list of organizations, including their profiles and details.

Latest updates on clinical trials, pharmaceuticals, and healthcare companies

DeepMed Research

|

Filters

Study Phase

Early Phase 1

Phase 1

Phase 1/2

Phase 2

Phase 2/3

Phase 3

Phase 4

Not Applicable

Recruitment Status

Recruiting

Not yet recruiting

Active, not recruiting

Completed

Suspended

Terminated

Withdrawn

Study Type

Interventional

Observational

Expanded Access

Others

Eligibility Sex

All

Female

Male

Healthy Volunteers

All

Include

Exclude

Found 407 clinical trials|View Analysis

Sort by:

Need a comprehensive medical report on "University of Cologne"?

Analyze the latest clinical research and treatment options

Summarize scientific findings from medical journals

Evaluation of the Antipsychotic Efficacy of Cannabidiol in Acute Schizophrenic Psychosis

Phase 2

Completed

Conditions: Schizophrenia

Interventions: Drug: Cannabidiol
Drug: Amisulpride

First Posted Date: 2008-03-05

Last Posted Date: 2008-03-18

Lead Sponsor: University of Cologne

Target Recruit Count: 42

Registration Number: NCT00628290

Locations: 🇩🇪
University of Cologne, Dept. of Psychiatry and Psychotherapy, Cologne, NRW, Germany

Effectiveness of UVA1-irradiation in the Treatment of Early Skin Fibrosis in Patients Suffering From Systemic Sclerosis

Phase 1

Terminated

Conditions: Systemic Scleroderma
Systemic Sclerosis

Interventions: Other: UVA1

First Posted Date: 2008-03-05

Last Posted Date: 2017-05-31

Lead Sponsor: Nicolas Hunzelmann

Target Recruit Count: 9

Registration Number: NCT00628797

Locations: 🇩🇪
University of Tuebingen, Dept. of Dermatology, Tuebingen, BW, Germany
🇩🇪
University of Cologne, Dept. of Dermatology, Cologne, NRW, Germany

Combined Treatment of Sorafenib and Pegylated Interferon α2b in Stage IV Metastatic Melanoma

Phase 2

Completed

Conditions: Melanoma

Interventions: Drug: Sorafenib
Drug: pegylated interferon α-2b

First Posted Date: 2008-02-26

Last Posted Date: 2011-01-12

Lead Sponsor: University Hospital Schleswig-Holstein

Target Recruit Count: 55

Registration Number: NCT00623402

Locations: 🇩🇪
Dpt. of Dermatology, University of Hannover, Hannover, Germany
🇩🇪
Dpt. of Dermatology, Humboldt University, Berlin, Germany
🇩🇪
Dept. of Dermatology, Elbe Klinikum, Buxtehude, Germany

and more 7 locations

PTK/ZK in Disseminated Malignant Melanoma

Phase 1

Terminated

Conditions: Melanoma

Interventions: Drug: PTK787/ZK 222584
Drug: Dacarbazine

First Posted Date: 2008-02-14

Last Posted Date: 2021-10-06

Lead Sponsor: Michael Weichenthal

Target Recruit Count: 9

Registration Number: NCT00615160

Locations: 🇩🇪
Dpt. of Dermatology, University of Frankfurt, Frankfurt/Main, Germany
🇩🇪
Dpt. of Dermatology, University of Cologne, Koeln, Germany
🇩🇪
Dpt. of Dermatology; UK-SH Campus Kiel, Germany, Kiel, Germany

and more 1 locations

Isoniazid Dose Adjustment According to NAT2 Genotype (IDANAT2)

Phase 3

Terminated

Conditions: Pulmonary Tuberculosis

Interventions: Drug: isoniazid

First Posted Date: 2007-12-12

Last Posted Date: 2011-02-28

Lead Sponsor: University of Cologne

Target Recruit Count: 900

Registration Number: NCT00571753

Locations: 🇩🇪
Helios Klinikum Emil von Behring GmbH, Berlin, Germany
🇧🇬
Specialized Hospital for Active Treatment of Pulmonary Diseases "Sveta Sofia", Sofia, Bulgaria
🇩🇪
Karl-Hansen-Klinik, Bad Lippspringe, Germany

and more 9 locations

A Rollover Study for Subjects Participating in the Control Arm of Study VX06-950-106, VX05-950-104 and VX05-950-104EU Whose Plasma Hepatitis C Virus (HCV) Ribonucleic Acid (RNA) Levels Did Not Respond to Therapy

Phase 2

Completed

Conditions: Hepatitis C

Interventions: Drug: Telaprevir
Drug: Ribavirin
Drug: Pegylated interferon alfa 2a

First Posted Date: 2007-09-26

Last Posted Date: 2014-08-05

Lead Sponsor: Vertex Pharmaceuticals Incorporated

Target Recruit Count: 117

Registration Number: NCT00535847

Locations: 🇺🇸
Atlanta Gastroenterology Associates, Atlanta, Georgia, United States
🇺🇸
South Denver Gastroenterology, Englewood, Colorado, United States
🇺🇸
University of Florida, Gainesville, Florida, United States

and more 38 locations

HD18 for Advanced Stages in Hodgkins Lymphoma

Phase 3

Completed

Conditions: Hodgkins Lymphoma

Interventions: Drug: Rituximab
Drug: BEACOPP escalated

First Posted Date: 2007-08-13

Last Posted Date: 2020-11-13

Lead Sponsor: University of Cologne

Target Recruit Count: 1500

Registration Number: NCT00515554

Locations: 🇩🇪
1st Dept. of Medicine, Cologne University Hospital, Cologne, Germany

PVAG-14 Pilot for Intermediate Stages Hodgkin Lymphoma

Phase 2

Terminated

Conditions: Hodgkin Lymphoma

Interventions: Drug: prednisone
Drug: vinblastine
Drug: doxorubicin
Drug: gemcitabine

First Posted Date: 2007-08-08

Last Posted Date: 2015-12-03

Lead Sponsor: University of Cologne

Registration Number: NCT00512980

Locations: 🇩🇪
University of Cologne, Cologne, Germany

Rituximab and Involved Field Radiotherapy in Early Stage Follicular Lymphoma

Phase 2

Completed

Conditions: Lymphoma, Malignant

First Posted Date: 2007-07-31

Last Posted Date: 2020-01-06

Lead Sponsor: Klaus Herfarth, MD

Target Recruit Count: 85

Registration Number: NCT00509184

Locations: 🇩🇪
University of Cologne, Cologne, Germany
🇩🇪
University of Dresden, Dresden, Germany
🇩🇪
University of Kiel, Kiel, Germany

and more 14 locations

Development and Pilot Evaluation of Modified Cognitive Behavioural Therapy for Adolescents With Early Onset Psychosis

Phase 2

Conditions: Schizophrenia
Delusional Disorder
Psychotic Disorders
Schizoaffective Disorder
Schizophreniform Disorder

First Posted Date: 2007-04-27

Last Posted Date: 2009-02-20

Lead Sponsor: University of Cologne

Target Recruit Count: 42

Registration Number: NCT00465920

Locations: 🇩🇪
Department of Psychiatry University Cologne, Cologne, North Rhine-Westphalia, Germany

Prev
1
33
34
35
36
37
41
Next

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy